Insider · CIK 0001604457

Walker Neal

Reports to the SEC for 2 companies · LEXINGTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001604457

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-09	ALDXAldeyra Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+70K sh	—	—	70,000
2026-06-09	ALDXAldeyra Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+3,318 sh	—	—	3,318
2026-02-03	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+63.5K sh	—	—	1,562,497
2026-02-03	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−18.6K sh	$3.47	−$64.6K	1,543,886
2026-02-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−63.5K sh	—	—	190,425
2026-02-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Director, CEO	AAward	+275K sh	—	—	274,800
2026-02-02	ACRSAclaris Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	Director, CEO	AAward	+962K sh	—	—	961,700
2026-01-02	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+29.2K sh	—	—	1,508,974
2026-01-02	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−9,952 sh	$2.88	−$28.7K	1,499,022
2026-01-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−29.2K sh	—	—	30,034
2025-06-10	ALDXAldeyra Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+62.7K sh	—	—	62,728
2025-06-10	ALDXAldeyra Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+2,413 sh	—	—	2,413
2025-05-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+9,467 sh	—	—	1,482,799
2025-05-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−2,975 sh	$1.38	−$4,105.5	1,479,824
2025-05-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−9,467 sh	—	—	0
2025-04-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+9,467 sh	—	—	1,476,374
2025-04-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−3,042 sh	$1.48	−$4,502.16	1,473,332
2025-04-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−9,467 sh	—	—	9,467
2025-03-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+9,466 sh	—	—	1,470,184
2025-03-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−3,277 sh	$1.99	−$6,521.23	1,466,907
2025-03-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−9,466 sh	—	—	18,934
2025-02-03	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Director, CEO	AAward	+254K sh	—	—	253,900
2025-02-03	ACRSAclaris Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	Director, CEO	AAward	+889K sh	—	—	888,800
2025-02-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+9,467 sh	—	—	1,464,277
2025-02-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−3,559 sh	$2.48	−$8,826.32	1,460,718
2025-02-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−9,467 sh	—	—	28,400
2025-01-02	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+29.1K sh	—	—	1,468,342
2025-01-02	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−13.5K sh	$2.48	−$33.6K	1,454,810
2025-01-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award	Director, CEO	AAward	+88.3K sh	—	—	88,333
2025-01-02	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−29.1K sh	—	—	59,184
2025-01-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+9,467 sh	—	—	1,443,097
2025-01-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−3,904 sh	$2.48	−$9,681.92	1,439,193
2025-01-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−9,467 sh	—	—	37,867
2024-12-04	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+119K sh	$1.52	+$181K	1,501,973
2024-12-04	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−68.3K sh	$3.76	−$257K	1,433,630
2024-12-04	ACRSAclaris Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Director, CEO	MExercise/Conversion	−119K sh	—	—	0
2024-12-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+9,466 sh	—	—	1,385,854
2024-12-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−2,721 sh	$4.07	−$11.1K	1,383,133
2024-12-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−9,466 sh	—	—	47,334
2024-11-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+9,467 sh	—	—	1,379,109
2024-11-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−2,721 sh	$2.09	−$5,686.89	1,376,388
2024-11-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−9,467 sh	—	—	56,800
2024-10-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+9,467 sh	—	—	1,372,364
2024-10-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−2,722 sh	$1.18	−$3,211.96	1,369,642
2024-10-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−9,467 sh	—	—	66,267
2024-09-01	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+9,466 sh	—	—	1,365,619
2024-09-01	ACRSAclaris Therapeutics, Inc.F Tax Payment	Director, CEO	FTax Payment	−2,722 sh	$1.18	−$3,211.96	1,362,897
2024-09-01	ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, CEO	MExercise/Conversion	−9,466 sh	—	—	75,734
2024-08-09	ACRSAclaris Therapeutics, Inc.M Exercise/Conversion	Director, CEO	MExercise/Conversion	+43.5K sh	$0.72	+$31.4K	1,356,153
2024-08-09	ACRSAclaris Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Director, CEO	MExercise/Conversion	−43.5K sh	—	—	0

Recent filings

Accepted (ET)
Jun 114
Walker Neal0001193125-26-267605
SEC(opens sec.gov)
Feb 64
Walker Neal0001604457-26-000007
SEC(opens sec.gov)
Feb 54
Walker Neal0001604457-26-000005
SEC(opens sec.gov)
Jan 54
Walker Neal0001604457-26-000003
SEC(opens sec.gov)
Jun 124
Walker Neal0000950170-25-085489
SEC(opens sec.gov)
May 54
Walker Neal0001415889-25-011955
SEC(opens sec.gov)
Apr 34
Walker Neal0001415889-25-009937
SEC(opens sec.gov)
Mar 44
Walker Neal0001415889-25-006496
SEC(opens sec.gov)

Companies

Address

C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE

LEXINGTON, MA, 02421